RA NOT TREATED GROUP  NO 35
VALUE ( M ± SD )

  RA sero-
NO 18
VALUE ( M ± SD )

  RA sero+
NO 17
VALUE ( M ± SD )

  CONTROL
HEALTHY GROUP  NO 35
VALUE ( M ± SD )

   

 

Positive / Negative

 

Positive / Negative

 

Positive / Negative

 

Positive / Negative

AAP  + > 0,75
( U/mmol/creatinin )
24/11
1,06 (± 0,54 )
( 0,35-2,46 )
14/4
1,14 (± 0,48 )
( 0,45-2,46 )
10/7
0,98 (± 0,59 )
( 0,35-2,30 )
7/28
0,74 (± 0,43 )
( 0,02-1,75 )
γ-GT + >1,80
( U/mmol/creatinin )
16/19
1,80 (± 0,97 )
( 0,45-4,40 )
10/8
1,81 (± 0,80 )
( 0,70-3,50 )
6/11
1,79 (± 1,15 )
( 0,45-4,40 )
6/29
1,51 (± 0,70 )
( 0,35-2,84 )
2 MICROGLOBULIN
+> 0,19 ( mg/L )
0/35
0,05 (± 0,03 )
( 0,01-0,15 )
0/18
0,06 (± 0,04 )
( 0,01-0,15 )
0/17
0,04 (± 0,03 )
( 0,01-0,13 )
1/34
0,08 (± 0,06 )
( 0,02-0,25 )
CREATININE SERUM
<49-109 >mol/L
3/32
67,55 (± 14,76 )
(41-108)
1/17
68,24 (± 14,16 )
(44-108)
2/15
66,82 (± 15,77 )
(41-99)
2/33
74,95 (± 19,72 )
(44-135)
 CREATININE URINA
<7-17>mol/dU
9/26
10,41 (± 4,71 )
(3,1-25,4)
6/12
9,26 (± 4,54 )
(3,1-18)
3/14
11,62 (± 4,72 )
(5,8-25,4)
5/30
9,15 (± 4,22 )
(1,8-20,4)
UREA SERUM
+ >7,8 mmol/L
4/31
5,66 (± 1,46 )
(3,00-8,60)
0/18
5,52 (± 1,33 )
(3,00-7,5)
4/13
5,82 (± 1,62 )
(3,80-8,6)
1/34
4,94 (± 1,28 )
(2,50-7,2)
GFR
+ >90 ml/min
14/21
99,19 (± 24,46 )
(56,08-157,30)
7/11
99,19 (± 24,46 )
(64,67-142,59)
7/10
99,19 (± 25,22 )
(56,08-157,30)
4/31
113,80 (± 30,86 )
(69,98-177,74)
DAS 28
+ > 3,2
28/7
4,79 (± 1,56 )
(1,85-7,03)
13/5
4,56 (± 1,76 )
(1,85-7,03)
15/2
5,04 (± 1,33 )
(2,47-6,83)
0/35
0,00 (± 0,00 )
(0,00-0,00)
MORNING STIFFNESS
+> 0 min
26/9
43,20 (± 65,13 )
( 0-300 )
14/4
57,50 (± 81,40 )
(0-300)
12/5
28,05 (± 38,72 )
(0-120)
0/35
0,00 (± 0,00 )
(0,00-0,00)
RF
+30 > IU/ml
17/18
346,15 (± 625,22)
(0,00-1920)
0/18
0,00 (± 0,00 )
(0,00-0,00)
17/0
712,67 (± 743,72)
(30-1920)
2/33
13,71 (± 38,73 )
(0,00-120)
CRP
+12 > mg/L
14/21
46,86 (± 79,19 )
(0,00-384)
3/15
8,66 (± 24,62 )
(0,00-96)
13/4
87,31 (± 96,44 )
(0,00-384)
4/31
5,48 (± 12,80 )
(0,00-48)
ESR
+>16
27/8
48,62 (± 39,81 )
(2,0-120)
13/5
43,94 (± 39,82 )
(2,0-120)
14/3
53,58 (± 40,39 )
(5,0-120)
4/31
9,42 (± 8,21 )
(2,0-44)
ACPA
> 1,26
23/12
1,71 (± 0,69 )
(0,92-3,0)
11/7
1,56 (± 0,59 )
(0,93-2,6)
12/5
1,87 (± 0,77 )
(0,92-3,0)
1/34
0,95 (± 0,10 )
(0,90-1,38)
Table 1: AAP,γ-GT, β2 M and other laboratory variables in RA and control healthy group.